Janssen Sciences Ireland UC, a Johnson & Johnson company, announced the decision to halt development of its hepatitis C treatment combination JNJ-4178.
Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors.
Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July 2017’s big clinical trial setback in the disease.
French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.
Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.
Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.
Otonomy Inc. suspended developing its drug for Meniere’s disease, a chronic disorder of the inner ear, after it failed a late-stage trial.
Two years after forging a collaborative and licensing agreement with Southern California-based Inhibrx LLC, Five Prime Therapeutics Inc. walked away from the deal that includes an early cancer drug candidate.
Structural improvements over the last decade to Houston hospitals have helped them to avoid devastation like Hurricane Katrina in New Orleans in 2005, but the pounding it received from Tropical Storm Harvey is expected to financially hobble many already strained Texas medical centers.